Clinical effects of selective thromboxane A2 synthetase inhibitor in patients with nephrotic syndrome.
To determine if a selective thromboxane (TX)A2 synthetase inhibitor is clinically effective for the treatment of nephrotic syndrome, 11 patients with nephrotic syndrome were treated only with OKY-046, (E)-3-4-(1-imidazolylmethyl)phenyl-2-propenoic acid hydrochloride monohydrate, for at least 8 weeks. Urinary excretion of protein, TXB2, 2,3-dinor-TXB2, and beta-N-acetyl-D-glucosaminidase decreased with OKY-046. Creatinine clearance value, and urinary excretion of 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha), however, did not show any significant change, while serum albumin level increased. Two patients with minimal change nephrotic syndrome showed complete remission only with OKY-046. These results demonstrate that the selective TXA2 synthetase inhibitor is an effective drug for the treatment of chronic glomerulonephritis accompanied by nephrotic syndrome.
Niwa
T
T
Department of Internal Medicine, Nagoya University Branch Hospital, Japan.
Maeda
K
K
Shibata
M
M
Yamada
K
K
D015121:6-Ketoprostaglandin F1 alpha / Q000652:urine; D000179:Acrylates / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D005921:Glomerulonephritis / Q000150:complications / Q000188:drug therapy / Q000652:urine; D006801:Humans; D008297:Male; D008689:Methacrylates / Q000378:metabolism / Q000627:therapeutic use*; D008875:Middle Aged; D009402:Nephrosis, Lipoid / Q000188:drug therapy; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000209:etiology / Q000652:urine; D011507:Proteinuria / Q000652:urine; D013929:Thromboxane B2 / Q000031:analogs & derivatives / Q000652:urine; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D000179:Acrylates; D008689:Methacrylates; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; C028965:2,3-dinor-thromboxane B2; D013930:Thromboxane-A Synthase; C034364:ozagrel